News Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

End-of-day quote Nyse Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
2.02 ^USD	-3.35%		-4.04%	-8.18%

Jul. 01	Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	CI
Jun. 28	Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Can Fite BioPharma : Fite Presentation	05:39am	PU
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	Jul. 01	AQ
Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson	Jul. 01	CI
Can Fite BioPharma : Other Report or Announcement	Jun. 28	PU
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	Jun. 28	BU
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	Jun. 28	CI
Can Fite BioPharma : Other Report or Announcement	Jun. 26	PU
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	Jun. 24	PU
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	Jun. 24	CI
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	Jun. 24	BU
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	PU
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	BU
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	Jun. 10	CI
Transcript : Can-Fite BioPharma Ltd. - Special Call	Jun. 06
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	BU
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	Jun. 05	CI
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	May. 29	BU
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	May. 27	BU
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	May. 23	BU
Can Fite BioPharma : Immediate Report of Meeting	May. 22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

Summary

Filters